PEP/NEWS — Peptide intel. Daily.

Join Thrive Market today and get $20 off your first three orders plus a free $60 gift! http://thrivemarket.com/ThomasDeLauer This video does contain a paid partnership with a brand that helps to support this channel. It is because of brand

Attia reviews fresh data on GLP-1 receptor agonists (a class that includes semaglutide) and lean mass loss during weight reduction. His read: with adequate protein and resistance training, lean mass loss is far smaller than feared.

Older mice fail to ramp up autophagy (the cell's waste-clearing system) under toxic stress, leaving kidneys vulnerable to acute injury. Boosting autophagic flux in aged animals restored protection — pointing to a potential intervention target.

Researchers targeted GPR40, a receptor in thymus epithelial cells, and slowed the organ's age-related shrinkage in mice. The thymus trains immune T cells — its decline is a central driver of aging immunity.

Lifelong restriction of the amino acid valine improved health and extended lifespan in mice, but the effects differed between males and females. The finding adds to growing evidence that dietary amino acid composition — not just calories — shapes longevity.

Senescent cells (aged, dysfunctional cells that resist normal death) hijack a nuclear protein called CTCF to rewrite which gene variants get produced. The mechanism is a new piece of the puzzle explaining how senescent cells spread dysfunction to surrounding tissue.

Blocking a specific molecular chain — CDK4/6–RARα–NF-κB — reduced the chronic inflammation that senescent cells produce and improved physical function in aging and post-chemotherapy mice. The NF-κB pathway is a key target in senolytic and anti-inflammatory peptide research.

Exosomes derived from mesenchymal stem cells (MSCs) reduced harmful metabolic changes in mouse livers with fatty liver disease. The approach bypasses many cell-therapy hurdles and builds on a growing body of exosome liver research.

A new editorial in Frontiers in Pharmacology frames the growing research agenda on stress, neuropeptides, and alcohol use disorder. The interplay between the stress axis and addictive behavior is emerging as a tractable peptide-modulation target.

The LATTICE trial returned negative results for lithium in Alzheimer's disease. Attia unpacks what the failure means — and what questions remain open for cognition-targeted intervention research.

Better mitochondrial oxidative capacity in muscle correlates with slower cognitive decline over up to ten years — but the protective effect differs between men and women. The finding links metabolic peptide research to brain health outcomes.

A large proteomics study found blood-based biomarker panels that can distinguish between different dementia types and track disease stage. The work moves toward blood tests that replace costly imaging in clinical research.